M3 Wake Research Network Acquires Pharmacology Research Institute (PRI)
FORT WASHINGTON, Pa. (PRWEB) September 27, 2018 -- M3 Wake Research, a clinical research subsidiary of M3 USA, the U.S. business segment of M3, Inc., a global healthcare technology, research, media, and marketing firm, acquired Pharmacology Research Institute (PRI).
Established in 1975, PRI conducts multispecialty clinical studies for domestic and international pharmaceutical companies, with a special expertise in psychiatry, neurology and gerontology. This acquisition solidifies the position of M3 Wake Research as a premier North American research network, with PRI enhancing M3 Wake Research’s expertise in Neuroscience. The acquisition of PRI expands the research organization to provide coast-to-coast coverage in the United States and incorporates communities of nearly 20 million people.
M3 entered the clinical research business in the U.S. in February 2018, via the acquisition of Wake Research, one of the largest independent Phase I-IV clinical trial site service companies in North America. Wake Research is an integrated network of 12 research sites operating in seven states: Alabama, Arizona, California, Georgia, North Carolina, Tennessee, and Texas. PRI adds three California-based clinical trial facilities to M3 Wake Research’s existing network of research sites. These newly acquired sites are located in Los Alamitos/Long Beach, Orange County/Newport Beach, and Encino/San Fernando Valley.
“We are very excited about growing our clinical research business with this acquisition of Pharmacology Research Institute,” states Dr. Ella Grach, CEO of M3 Wake Research. “With its industry reputation for being patient focused and the ‘go-to site’ for neuroscience research, PRI will be a key part of our network. We see significant opportunities for additional growth, and we look forward to contributing to drug development and treatment of serious and widespread medical issues impacting the lives of millions of Americans, such as Alzheimer’s disease, multiple sclerosis, PTSD, depression, migraines, and more.” Dr. Grach adds.
PRI will be a complimentary clinical research asset to M3 Wake Research, which is based in the Research Triangle Park area of Raleigh, NC, and has built a combined database of more than 950,000 subjects to date. M3 Wake Research’s board certified physicians have completed more than 6,300 successful clinical trials in most major therapeutic areas, with particular expertise in gastroenterology, neuroscience, dermatology, endocrinology, immunology, and women’s health.
“All of us at M3 Wake Research look forward to working together with PRI to continue to provide excellent service to achieve the ultimate goal of improving patient care while remaining on the cutting edge of the medical arena,” adds Ella Grach, MD.
PRI will be integrated as part of the M3-Wake Research’s network and will benefit from M3 Wake’s industry leading capabilities such as centralized patient recruitment and retention, company-wide QA/QC program, in-house training program, and marketing/advertising services.
PRI is joining the family of M3 USA brands including MDLinx, a clinical education and medical news website, The Medicus Firm, a physician and advanced practitioner recruiting firm, and PracticeMatch, which provides healthcare employers with staffing resources such as job boards, career fairs, and a physician database. No further financial details of the transaction were made publicly available at this time.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net, vidal.fr, and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, France, Germany, Spain, Sweden, Japan, S. Korea, China and India. M3 Inc. provides services to healthcare and the life science industry. In addition to clinical research, these services include medical education, ethical drug promotion, market research, job recruitment, and clinic appointment services. M3 has offices in Tokyo, New York, Fort Washington, PA, Dallas, St Louis, Oxford, London, Paris, Madrid, Frankfurt, Beijing, and Seoul.
Andrea Clement, M3 USA, http://usa.m3.com, +1 (618) 979-5997, [email protected]
Share this article